-Bloomberg
Biogen’s New Alzheimer’s Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer’s drug developed by Biogen Inc (NASDAQ:BIIB)…
Related Posts
Alnylam Announces FDA Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for
E.L.F. Beauty Announces ‘Electric Mood’
e.l.f. Cosmetics is rocking its new limited-edition Electric Mood collection, born from Beautyscape, e.l.f.'s annual competition which offers beauty's rising stars a once-in-a-lifetime chance to help build an
Global E Online Q2 EPS $(0.25) Misses $(0.01) Estimate, Sales $57.29M Beat $47.61M Estimate
Global E Online (NASDAQ:GLBE) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.01) by 2400 percent. The company reported quarterly sales of $57.29 million which beat the